IPHA
Price
$2.19
Change
+$0.01 (+0.46%)
Updated
Aug 15 closing price
Capitalization
208.55M
30 days until earnings call
QURE
Price
$16.18
Change
+$0.40 (+2.53%)
Updated
Aug 15 closing price
Capitalization
887.75M
72 days until earnings call
Interact to see
Advertisement

IPHA vs QURE

Header iconIPHA vs QURE Comparison
Open Charts IPHA vs QUREBanner chart's image
Innate Pharma SA
Price$2.19
Change+$0.01 (+0.46%)
Volume$7.3K
Capitalization208.55M
uniQure
Price$16.18
Change+$0.40 (+2.53%)
Volume$1.36M
Capitalization887.75M
IPHA vs QURE Comparison Chart in %
Loading...
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IPHA vs. QURE commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPHA is a Hold and QURE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (IPHA: $2.19 vs. QURE: $16.18)
Brand notoriety: IPHA and QURE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IPHA: 64% vs. QURE: 113%
Market capitalization -- IPHA: $208.55M vs. QURE: $887.75M
IPHA [@Biotechnology] is valued at $208.55M. QURE’s [@Biotechnology] market capitalization is $887.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IPHA’s FA Score shows that 1 FA rating(s) are green whileQURE’s FA Score has 0 green FA rating(s).

  • IPHA’s FA Score: 1 green, 4 red.
  • QURE’s FA Score: 0 green, 5 red.
According to our system of comparison, IPHA is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IPHA’s TA Score shows that 6 TA indicator(s) are bullish while QURE’s TA Score has 5 bullish TA indicator(s).

  • IPHA’s TA Score: 6 bullish, 4 bearish.
  • QURE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, IPHA is a better buy in the short-term than QURE.

Price Growth

IPHA (@Biotechnology) experienced а +4.29% price change this week, while QURE (@Biotechnology) price change was +21.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

IPHA is expected to report earnings on Sep 17, 2025.

QURE is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QURE($888M) has a higher market cap than IPHA($209M). IPHA YTD gains are higher at: 19.022 vs. QURE (-8.381).
IPHAQUREIPHA / QURE
Capitalization209M888M24%
EBITDAN/A-119.56M-
Gain YTD19.022-8.381-227%
P/E RatioN/AN/A-
RevenueN/A14.3M-
Total CashN/A377M-
Total DebtN/A66.7M-
FUNDAMENTALS RATINGS
IPHA vs QURE: Fundamental Ratings
IPHA
QURE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4539
P/E GROWTH RATING
1..100
3392
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IPHA's Valuation (76) in the null industry is in the same range as QURE (78) in the Biotechnology industry. This means that IPHA’s stock grew similarly to QURE’s over the last 12 months.

IPHA's Profit vs Risk Rating (100) in the null industry is in the same range as QURE (100) in the Biotechnology industry. This means that IPHA’s stock grew similarly to QURE’s over the last 12 months.

IPHA's SMR Rating (98) in the null industry is in the same range as QURE (100) in the Biotechnology industry. This means that IPHA’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (39) in the Biotechnology industry is in the same range as IPHA (45) in the null industry. This means that QURE’s stock grew similarly to IPHA’s over the last 12 months.

IPHA's P/E Growth Rating (33) in the null industry is somewhat better than the same rating for QURE (92) in the Biotechnology industry. This means that IPHA’s stock grew somewhat faster than QURE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IPHAQURE
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 5 days ago
88%
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
74%
Advances
ODDS (%)
Bullish Trend 13 days ago
72%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
83%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
IPHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOGP0.04N/A
+1.21%
Dogecoin Cash Inc.
GNNSF2.19N/A
N/A
Genscript Biotech Corp
JPHLF9.21N/A
N/A
JAPAN POST HLDGS CO LTD
TSKFF0.46-0.01
-1.75%
Talisker Resources Ltd.
BELGF0.59-0.02
-3.09%
Bellevue Gold, Ltd.

IPHA and

Correlation & Price change

A.I.dvisor tells us that IPHA and TNXP have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IPHA and TNXP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHA
1D Price
Change %
IPHA100%
+0.65%
TNXP - IPHA
30%
Poorly correlated
-13.81%
TECH - IPHA
29%
Poorly correlated
-0.26%
QSI - IPHA
27%
Poorly correlated
-1.79%
QURE - IPHA
26%
Poorly correlated
+2.53%
ENTA - IPHA
25%
Poorly correlated
+3.36%
More